ascendis transcon glp-1 program Pharma announced that the U.S. Food and Drug Administration (FDA) has approved Yorvipath (palopegteriparatide, PTH,) injection as the First and Only treatment for adults with hyperparathyroidism. Palopegteriparatide is a prodrug Ascendis Pharma submits MAA for
Description
Other GLP-1 medications Several other GLP-1 receptor agonists have also been affected by Anthem coverage changes
doi: 10.3390/ijms22147475 [DOI] [PMC free article] [PubMed] [Google Scholar] 78
For a broader look at all Aetna denial types and their action paths, see the Aetna denied claim guide
No study yet extends beyond one year
M., van der Veen, D
The results showed that intra-articular injection of liraglutide alleviated pain-related behavior in in vivo sodium monoiodoacetate OA mouse model, which was probably driven by the GLP-1R-mediated anti-inflammatory activity of liraglutide
